Schmitt Martin, Menoux Inès, Chambrelant Isabelle, Hild Carole, Petit Thierry, Mathelin Carole, Noël Georges
Radiotherapy Department, Strasbourg Europe Cancer Institute, 17 Rue Albert Calmette, Strasbourg CEDEX 67200, France.
Radiotherapy Department, Strasbourg Europe Cancer Institute, 17 Rue Albert Calmette, Strasbourg CEDEX 67200, France.
Transl Oncol. 2022 Aug;22:101456. doi: 10.1016/j.tranon.2022.101456. Epub 2022 May 21.
Several studies have shown that simultaneous integrated boost provides better dose homogeneity, improves the biologically effective dose-volume histogram and reduces treatment time compared to sequential boost in breast cancer.
We conducted a systematic review of published trials evaluating simultaneous integrated boost in hypofractionated radiotherapy to analyze the results in terms of overall survival, local control, early and late side effects, and radiotherapy techniques used.
Upon 9 articles, the prescribed dose to the whole breast varied from 40 to 46.8 Gy. The number of fractions varies from 15 to 20 fractions. The prescribed dose per fraction to the boost varied from 2.4 Gy per fraction to 3.4 Gy per fraction for a total boost dose from 48 to 52.8 Gy.
Simultaneous integrated boost seems effective and safe when given hypofractionated whole-breast irradiation but needs to be validated in prospective trials.
多项研究表明，与乳腺癌序贯加量放疗相比，同步整合加量放疗能提供更好的剂量均匀性，改善生物等效剂量体积直方图，并缩短治疗时间。
我们对已发表的评估大分割放疗中同步整合加量放疗的试验进行了系统综述，以分析总生存率、局部控制率、早期和晚期副作用以及所采用的放疗技术方面的结果。
在9篇文章中，全乳的处方剂量为40至46.8 Gy。分次次数从15次至20次不等。加量放疗每次的处方剂量从每次2.4 Gy至每次3.4 Gy不等，总加量剂量为48至52.8 Gy。
大分割全乳照射时采用同步整合加量放疗似乎有效且安全，但需要在前瞻性试验中进行验证。
Zotero 插件